Choosing the right biologic treatment for individual patients with severe asthma - lessons learnt from Picasso

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F24%3A10483361" target="_blank" >RIV/00669806:_____/24:10483361 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/24:10483361 RIV/00216208:11140/24:10483361 RIV/00064190:_____/24:10001317

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fuSyKQ6ZfR" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=fuSyKQ6ZfR</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rmed.2024.107766" target="_blank" >10.1016/j.rmed.2024.107766</a>

Result language

angličtina

Original language name

Choosing the right biologic treatment for individual patients with severe asthma - lessons learnt from Picasso

Original language description

Severe asthma represents a true challenge for clinicians from two basic perspectives, i.e.: a rational assessment of the underlying endo/phenotype and the subsequent selection of the best fitted (personalized) and effective treatment. Even though asthma is a heterogeneous disease, in the majority of therapy-compliant patients, it is possible to achieve (almost) complete disease control or even remission through conventional and quite uniform step-based pharmacotherapy, even without phenotyping. However, the absence of deeper assessment of individual patients revealed its handicap to its fullest extent during the first years of the new millennium upon the launch of biological therapeutics for patients with the most severe forms of asthma. The introduction of differentially targeted biologics into clinical practice became a challenge in terms of understanding and recognizing the etiopathogenetic heterogeneity of the asthmatic inflammation, pheno/endotyping, and, consequently, to choose the right biologic for the right patient. The answers to the following three questions should lead to correct identification of the dominant pheno/endotype: Is it really (severe) asthma? Is it eosinophilic asthma? If eosinophilic, is it (predominantly) allergen-driven? The identification of the best achievable and relevant alliance between endotypes and phenotypes (&quot;euphenotypes&quot;) should be based not only on the assessment of the actual clinical characteristics and laboratory biomarkers, but more importantly, on the evaluation of their development and changes over time. In the current paper, we present a pragmatic three-step approach to severe asthma diagnosis and management.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Respiratory Medicine

ISSN

0954-6111

e-ISSN

1532-3064

Volume of the periodical

234

Issue of the periodical within the volume

November–December

Country of publishing house

GB - UNITED KINGDOM

Number of pages

15

Pages from-to

107766

UT code for WoS article

001315285000001

EID of the result in the Scopus database

2-s2.0-85203542225